EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ion Beam Applications's Enterprise Value is €538.4 Mil.
Ion Beam Applications's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-38.4 Mil. Therefore, Ion Beam Applications's EV-to-FCF for today is -14.03.
The historical rank and industry rank for Ion Beam Applications's EV-to-FCF or its related term are showing as below:
FRA:IOB'
s EV-to-FCF Range Over the Past 10 Years
Min: -53.93 Med: -8.52 Max: 30.91
Current: -14.03
During the past 13 years, the highest EV-to-FCF of Ion Beam Applications was 30.91. The lowest was -53.93. And the median was -8.52.
FRA:IOB's EV-to-FCF is ranked worse than 100% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 22.765
vs FRA:IOB: -14.03
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ion Beam Applications (FRA:IOB) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ion Beam Applications's PE Ratio (TTM) for today is calculated as:
Ion Beam Applications's share price for today is €16.44.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ion Beam Applications's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.420.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Ion Beam Applications's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ion Beam Applications EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ion Beam Applications's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ion Beam Applications's EV-to-FCF falls into.
Ion Beam Applications's current Enterprise Value is €538.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ion Beam Applications's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-38.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ion Beam Applications (FRA:IOB) has a EV-to-FCF of -14.03 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ion Beam Applications and its competitors. According to the industry distribution chart, Ion Beam Applications ranks #999999 out of 418 companies in the Medical Devices & Instruments industry.
Is Ion Beam Applications' EV-to-FCF too high?
Ion Beam Applications' current EV-to-FCF is -14.03. Based on the distribution chart, Ion Beam Applications ranks #999999 out of 418 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Ion Beam Applications has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ion Beam Applications' EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ion Beam Applications ranks #999999 out of 418 companies for EV-to-FCF. This places Ion Beam Applications in the lower half of its industry. The industry median EV-to-FCF is 22.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.77, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ion Beam Applications and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ion Beam Applications's current EV-to-FCF is -14.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ion Beam Applications stock overvalued right now?
Based on GuruFocus' analysis, Ion Beam Applications (FRA:IOB) is currently considered Fairly Valued. The stock's GF Value™ is €15.56, compared to a current price of €16.44 — trading 5.7% above its estimated fair value. The current EV-to-FCF is -14.03. Ion Beam Applications' overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ion Beam Applications (FRA:IOB), the current EV-to-FCF is -14.03 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ion Beam Applications (FRA:IOB) Overvalued in 2026?
Based on GuruFocus' analysis, Ion Beam Applications stock appears to be overvalued.
The current stock price of €16.44 is trading 5.7% above its estimated GF Value™ of €15.56.
GuruFocus considers Ion Beam Applications to be Fairly Valued.
Key valuation signals for FRA:IOB:
EV-to-FCF: -14.03
GF Value™: €15.56 vs. price of €16.44 (5.7% above fair value)
No single metric tells the full story. See the FRA:IOB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in three segments: IBA Clinical, including Proton Therapy and Dosimetry; IBA Technologies; and IBA Corporate. Proton therapy and other accelerators contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, China, Germany, and India.
77GF Score
Get the complete analysis for FRA:IOB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IOB has been successfully added to your 
